{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:31:59Z","timestamp":1790285519594,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["2015-NI48002-00, 2016-NG48004-00"],"award-info":[{"award-number":["2015-NI48002-00, 2016-NG48004-00"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["NIH 4800-4845-300"],"award-info":[{"award-number":["NIH 4800-4845-300"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["4800-4859-300"],"award-info":[{"award-number":["4800-4859-300"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T13:42:05Z","timestamp":1525527725000},"page":"3445-3452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Heeji","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ju","family":"In","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung","family":"Sik Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyung Tae","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ki","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Keun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Ju","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June-Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2018.05.005_b0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3949\/ccjm.81a.13132","article-title":"Hand, foot, and mouth disease: identifying and managing an acute viral syndrome","volume":"81","author":"Repass","year":"2014","journal-title":"Cleve Clin J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2018.05.005_b0010","doi-asserted-by":"crossref","first-page":"e52073","DOI":"10.1371\/journal.pone.0052073","article-title":"Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009\u20132011","volume":"7","author":"Lu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.05.005_b0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12985-016-0567-6","article-title":"Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines","volume":"13","author":"Ang","year":"2016","journal-title":"Virol J"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.005_b0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jmii.2011.01.031","article-title":"Clinical and epidemiologic features of Coxsackievirus A6 infection in children in northern Taiwan between 2004 and 2009","volume":"44","author":"Lo","year":"2011","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.005_b0025","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1186\/s40064-016-3307-x","article-title":"Outbreak of hand, foot, and mouth disease caused by coxsackievirus A6 in a Juku in Fengtai District, Beijing, China, 2015","volume":"5","author":"Li","year":"2016","journal-title":"Springerplus"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.005_b0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1875-9572(08)60023-6","article-title":"Enterovirus 71 in Taiwan","volume":"49","author":"Chang","year":"2008","journal-title":"Pediatr Neonatol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.005_b0035","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3201\/eid1802.111147","article-title":"Hand, foot, and mouth disease caused by coxsackievirus A6, Japan, 2011","volume":"18","author":"Fujimoto","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.005_b0040","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.1111\/j.1469-0691.2012.03789.x","article-title":"Outbreak of hand, foot and mouth disease\/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study","volume":"18","author":"Mirand","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.vaccine.2018.05.005_b0045","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3201\/eid1509.090438","article-title":"Coxsackievirus A6 and hand, foot, and mouth disease Finland","volume":"15","author":"Osterback","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.005_b0050","doi-asserted-by":"crossref","first-page":"106","DOI":"10.47102\/annals-acadmedsg.V38N2p106","article-title":"Epidemiology and control of hand, foot and mouth disease in Singapore, 2001\u20132007","volume":"38","author":"Ang","year":"2009","journal-title":"Ann Acad Med Singapore"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.005_b0055","article-title":"Hand, foot, and mouth disease outbreak and coxsackievirus A6, northern Spain, 20Emerg","volume":"19","author":"Montes","year":"2013","journal-title":"Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.005_b0060","doi-asserted-by":"crossref","first-page":"O150","DOI":"10.1111\/1469-0691.12361","article-title":"Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain","volume":"20","author":"Cabrerizo","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"34","key":"10.1016\/j.vaccine.2018.05.005_b0065","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1016\/j.vaccine.2014.06.025","article-title":"A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice","volume":"32","author":"Ku","year":"2014","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.vaccine.2018.05.005_b0070","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1016\/j.vaccine.2014.08.064","article-title":"Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases","volume":"32","author":"Liu","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.005_b0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0264-410X(93)90197-6","article-title":"Principles of selective inactivation of viral genome. VIII. The influence of beta-propiolactone on immunogenic and protective activities of influenza virus","volume":"11","author":"Budowsky","year":"1993","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2018.05.005_b0080","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0264-410X(91)90031-Z","article-title":"Principles of selective inactivation of viral genome. VII. Some peculiarities in determination of viral suspension infectivity during inactivation by chemical agents","volume":"9","author":"Budowsky","year":"1991","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.005_b0085","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/biol.1995.0034","article-title":"Inactivation of DNA by beta-propiolactone","volume":"23","author":"Perrin","year":"1995","journal-title":"Biologicals"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.005_b0090","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.vaccine.2011.11.087","article-title":"Selection and characterization of vaccine strain for Enterovirus 71 vaccine development","volume":"30","author":"Chang","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2018.05.005_b0095","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.3390\/v7072803","article-title":"Optimization and characterization of candidate strain for coxsackievirus A16 inactivated vaccine","volume":"7","author":"Li","year":"2015","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.005_b0100","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4161\/hv.27295","article-title":"The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems","volume":"10","author":"Qi An","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.05.005_b0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1423-0127-21-31","article-title":"Animal models of enterovirus 71 infection: applications and limitations","volume":"21","author":"Wang","year":"2014","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.vaccine.2018.05.005_b0110","doi-asserted-by":"crossref","first-page":"34299","DOI":"10.1038\/srep34299","article-title":"Coxsackievirus A16 induced neurological disorders in young gerbils which could serve as a new animal model for vaccine evaluation","volume":"6","author":"Sun","year":"2016","journal-title":"Sci Rep"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2018.05.005_b0115","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1099\/vir.0.063560-0","article-title":"Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates","volume":"95","author":"Li","year":"2014","journal-title":"J Gen Virol"},{"issue":"22","key":"10.1016\/j.vaccine.2018.05.005_b0120","doi-asserted-by":"crossref","first-page":"11967","DOI":"10.1128\/JVI.00902-12","article-title":"A neonatal mouse model of coxsackievirus A16 for vaccine evaluation","volume":"86","author":"Mao","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.005_b0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2016.08.025","article-title":"A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6","volume":"134","author":"Yang","year":"2016","journal-title":"Antiviral Res"},{"issue":"41","key":"10.1016\/j.vaccine.2018.05.005_b0130","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1016\/j.vaccine.2016.08.033","article-title":"Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge","volume":"34","author":"Shen","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.005_b0135","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.coi.2011.08.003","article-title":"IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation","volume":"23","author":"Liao","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2018.05.005_b0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/B978-1-4160-3611-1.50006-4","article-title":"Vaccine immunology","volume":"5","author":"Siegrist","year":"2008","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.005_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","article-title":"The biology of interleukin-6","volume":"74","author":"Kishimoto","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.05.005_b0150","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-065X.2008.00706.x","article-title":"Interleukin-10: new perspectives on an old cytokine","volume":"226","author":"Mosser","year":"2008","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.005_b0155","doi-asserted-by":"crossref","first-page":"e30898","DOI":"10.1371\/journal.pone.0030898","article-title":"Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity","volume":"7","author":"Budimir","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.05.005_b0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jviromet.2016.04.013","article-title":"Analysis of the beta-propiolactone sensitivity and optimization of inactivation methods for human influenza H3N2 virus","volume":"235","author":"Sasaki","year":"2016","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2018.05.005_b0165","doi-asserted-by":"crossref","first-page":"616898","DOI":"10.1155\/2015\/616898","article-title":"Comparison of beta-Propiolactone and Formalin Inactivation on Antigenicity and Immune Response of West Nile Virus","volume":"2015","author":"Chowdhury","year":"2015","journal-title":"Adv Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2018.05.005_b0170","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1073\/pnas.84.21.7388","article-title":"Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: relationship to interleukin 5","volume":"84","author":"Yokota","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.05.005_b0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2016.02.008","article-title":"Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles","volume":"129","author":"Liu","year":"2016","journal-title":"Antiviral Res"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2018.05.005_b0180","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1099\/vir.0.79789-0","article-title":"Complete genome sequences of all members of the species Human enterovirus A","volume":"85","author":"Oberste","year":"2004","journal-title":"J Gen Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2018.05.005_b0185","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.3390\/v7112916","article-title":"Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice","volume":"7","author":"Caine","year":"2015","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.vaccine.2018.05.005_b0190","first-page":"e75","article-title":"EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases","volume":"5","author":"Mao","year":"2016","journal-title":"Emerg Microbes Infect"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.005_b0195","doi-asserted-by":"crossref","first-page":"e0178259","DOI":"10.1371\/journal.pone.0178259","article-title":"An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice","volume":"12","author":"In","year":"2017","journal-title":"PLoS One"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T13:06:43Z","timestamp":1693660003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18306108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":39,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X18306108"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}